Abstract:Background Neutrophil gelatinase-associated lipocalin (NGAL) is a widely studied biomarker in various clinical conditions, including cardiovascular diseases. Several studies have investigated its utility as a prognostic marker in acute decompensated heart failure (ADHF), including predicting the development of worsening renal function (WRF) or acute kidney injury (AKI). WRF and AKI are commonly defined using measurement of serum creatinine, which is a marker of glomerular filtration rather than tubular damage. An impetus for studying urinary NGAL (uNGAL) was to find an earlier marker of kidney injury prior to changes in serum creatinine. Importantly, it may also provide additional prognostic information on risk of death and readmission. Methods We systematically searched PubMed, Embase, Scopus, Web of Science, and CINAHL from inception until March 2023. We included studies of adult patients with ADHF that reported uNGAL levels and measured its association with outcomes of WRF/AKI, death, or readmission. We excluded pediatric, animal, or surgical populations, and conference abstracts. Meta-analysis of studies with similar effect measures was done using random effects model. Findings A total of 1694 studies were found, and we screened 1004 after removing 690 duplicates. After initial screening, we reviewed the full text of 37 studies. A total of 24 studies met the inclusion criteria. Most of the studies are observational. Three studies are post hoc analyses of the ROSE-AHF or CARRESS-HF trials, and five are sub-studies of a multicenter cohort (AKINESIS). The studies are marked by differences in design, timing of uNGAL measurement, definition of WRF/AKI, length of follow-up, analysis performed, and adjustment factors used. Six studies (total 1672 patients) evaluated the association of uNGAL with mortality after hospitalization for ADHF using multivariable models. Common adjustment factors include age, sex, systolic blood pressure, renal function (creatinine, BUN, or eGFR), and natriuretic peptide levels. Follow-up ranged from 180 days to over one year. The pooled hazard ratio (HR) for death using multivariable analysis (See Image) is 1.17 (95% CI 0.97, 1.42). Pooled effect sizes for other outcomes based on multivariable analyses are: WRF/AKI (odds ratio) 1.03 (95% CI 1.00, 1.06), and readmission (HR) 1.09 (95% CI, 0.85, 1.40). There is substantial heterogeneity in the studies, with I2 greater than 60-70%. Conclusion In patients with ADHF, urine NGAL does not independently predict development of WRF/AKI or subsequent outcomes (death or readmission).

Change and significance of NGAL in elderly patients with chronic kidney disease

Evaluation of serum neutrophil gelatinase‐associated lipocalin in older patients with chronic kidney disease

Predictive value of serum neutrophil gelatinase-associated lipocalin for acute kidney injury in high-risk elderly patients

The significance of urinary neutrophil gelatinase-associated lipocalin in the early diagnosis of diabetic nephropathy

Reduction in NGAL at 48 h predicts the progression to CKD in patients with septic associated AKI: a single-center clinical study

Clinical Significance of Serum Neutropbil Gelatinase-Associated Lipocalin Detection in Early Diagnosis of Acute Kidney Injury

Urine Neutrophil Gelatinase-associated Lipocalin (NGAL) for Prediction of Persistent AKI and Major Adverse Kidney Events

Are Urinary Tubular Injury Markers Useful in Chronic Kidney Disease? A Systematic Review and Meta Analysis

Correlation Analysis on Nonalcoholic Simple Fatty Liver and Estimated Glomerular Filtration Rate

Physiological study of NGAL and Cystatin C in chronic and acute kidney disease patients

Serum and Urinary Neutrophil Gelatinase-Associated Lipocalin Levels As Early Markers of the Renal Function in Patients with Urinary Stone-Induced Hydronephrosis.

Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes

Urinary neutrophil gelatinase-associated lipocalin: A potential biomarker for predicting rapid progression of drug-induced chronic tubulointerstitial nephritis.

Study on changes in the glomerular filtration rate with aging and their influencing factors

The utility of neutrophil gelatinase-associated Lipocalin (NGAL) as a marker of acute kidney injury (AKI) in critically ill patients

Prognostic Value Of Urine Neutrophil Gelatinase-Associated Lipocalin In Acute Decompensated Heart Failure: A Systematic Review And Meta-Analysis

[Urinary Neutrophil Gelatinase-Associated Lipocalin and Urinary Interleukin-18 in Early Diagnosis of Acute Kidney Injury in Critically Ill Patients].

. Clinical Significance of NLRP3 Inflammasome and Related Cell Moleculesin early Elderly Diabetic Kidney Disease

Using lipocalin as a prognostic biomarker in acute kidney injury

Clinical Impacts of Urinary Neutrophil Gelatinase-Associated Lipocalin in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention

Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C in Early Detection of Pediatric Acute Kidney Injury; a Diagnostic Accuracy Study